Lurbinectedin is a medication that is used in the treatment of certain types of cancer, specifically small cell lung cancer (SCLC) and metastatic triple-negative breast cancer (TNBC). While it can be an effective treatment option, it is important to be aware of the potential risks and side effects associated with its use.
According to the sources provided, here are some potential risks and side effects of lurbinectedin exposure:
1. Myelosuppression: Lurbinectedin can cause myelosuppression, which is a decrease in the production of blood cells. This can lead to low white blood cell count, low red blood cell count, and low platelet count. Patients may experience symptoms such as fatigue, weakness, increased susceptibility to infections, and easy bruising or bleeding [3].
2. Gastrointestinal toxicity: Lurbinectedin may cause gastrointestinal toxicity, including nausea, vomiting, diarrhea, and constipation. These side effects can affect the patient's quality of life and may require supportive care measures [3].
3. Hepatotoxicity: There have been reports of hepatotoxicity associated with lurbinectedin use. Patients may experience liver enzyme elevations, liver function abnormalities, and in rare cases, severe liver injury. Regular monitoring of liver function is recommended during treatment [3].
4. Cardiotoxicity: Lurbinectedin has the potential to cause cardiotoxicity, which can manifest as electrocardiogram (ECG) abnormalities or changes in cardiac function. Patients with pre-existing heart conditions or risk factors for heart disease may be more susceptible to this side effect. Close monitoring of cardiac function is advised [3].
5. Embryo-fetal toxicity: Lurbinectedin can cause harm to the developing fetus if used during pregnancy. It is classified as a pregnancy category D drug, meaning there is positive evidence of fetal risk based on human data. Women of childbearing potential should be advised to use effective contraception during treatment and for at least 6 months after the last dose [3].
It is important to note that the above list is not exhaustive, and there may be other risks and side effects associated with lurbinectedin use. It is essential for patients to discuss any concerns or questions with their healthcare provider before starting treatment.
Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] National Center for Biotechnology Information. Lurbinectedin: A Review in Metastatic Triple-Negative Breast Cancer. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054899/
[3] U.S. Food and Drug Administration. Lurbinectedin (Zepzelca) Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf